Physician profile
Christopher Burr
NPI 1982275186
$2,807.72
in general payments reported to CMS, 2019-2025
18 companies · $672 in 2025
The $672 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $121 · 2022: $175 · 2023: $764 · 2024: $1,076 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,509 · Education: $2.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,508.62 |
| Education | $2.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $552.20 | 2022-2024 | Infuse, Xiidra, Miebo |
| Abbvie INC. | $486.65 | 2023-2025 | Alphagan P, Lumigan, Vuity |
| Johnson & Johnson Vision Care, INC. | $386.07 | 2023-2025 | Acuvue |
| Sun Pharmaceutical Industries INC. | $270.36 | 2023-2025 | Cequa |
| Alcon Vision LLC | $202.18 | 2021-2025 | Tryptyr, Precision 1, Dailies Total1 |
| Coopervision INC. | $178.30 | 2021-2024 | Misight Contact Lens, Myday Contact Lens |
| Amgen INC. | $164.81 | 2024 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $128.87 | 2025 | Xdemvy |
| Horizon Therapeutics Plc | $122.55 | 2023 | Tepezza |
| Rxsight INC | $70.93 | 2022-2024 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Mallinckrodt Hospital Products INC. | $68.19 | 2022 | |
| Ucb, INC. | $64.66 | 2023-2024 | Zilbrysq, Rystiggo |
| Aerie Pharmaceuticals, INC. | $31.12 | 2021 | |
| Allergan, INC. | $21.76 | 2022 | |
| Dompe US, INC. | $18.32 | 2025 | Oxervate |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $15.76 | 2021 | |
| Oyster Point Pharma, INC. | $12.85 | 2022 | |
| Eyevance Pharmaceuticals LLC | $12.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Burr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.